lncRNA SNHG4通过EP300-SNHG4-GPX4轴抑制乳腺癌细胞铁死亡

doi:10.11904/j.issn.1002-3070.2023.03.004

实用肿瘤学杂志 ›› 2023, Vol. 37 ›› Issue (3): 215-223.doi: 10.11904/j.issn.1002-3070.2023.03.004

lncRNA SNHG4通过EP300-SNHG4-GPX4轴抑制乳腺癌细胞铁死亡

隋世尧¹, 郑玮², 杨子涵¹, 庞达¹

1.哈尔滨医科大学附属肿瘤医院乳腺外科一病区(哈尔滨 150081);
2.哈尔滨医科大学附属肿瘤医院门诊手术室

收稿日期:2023-03-13 修回日期:2023-06-19 出版日期:2023-06-28 发布日期:2023-08-07
通讯作者: 庞达,E-mail:pangdasir@163.com
作者简介:隋世尧,男,(1988-),博士,副主任医师,从事乳腺肿瘤的铁死亡机制研究。

LncRNA SNHG4 inhibits ferroptosis of breast cancer through EP300-SNHG4-GPX4 axis

SUI Shiyao¹, ZHENG Wei², YANG Zihan¹, PANG Da¹

1. Department of Breast Surgery,Harbin Medical University Cancer Hospital,Harbin,150081,China;
2. Department of Clean Operation,Harbin Medical University Cancer Hospital

Received:2023-03-13 Revised:2023-06-19 Online:2023-06-28 Published:2023-08-07

摘要/Abstract

摘要： 目的探讨lncRNA SNHG4在乳腺癌中的表达以及调控乳腺癌细胞铁死亡的作用机制。方法收集2017年1月—2018年12月于我院乳腺外科进行手术治疗的100例乳腺癌患者癌组织及距肿瘤边缘3~5 cm的癌旁组织,应用RT-PCR技术分析SNHG4在乳腺癌组织及配对癌旁组织中的表达。构建SNHG4敲降的乳腺癌MDA-MB-468细胞系及过表达SNHG4的乳腺癌Hs578T细胞系,CCK-8法测定SNHG4对乳腺癌细胞增殖能力的影响,应用铁含量测定试剂盒及MDA测定试剂盒检测铁及ROS改变,Western blot实验检测GPX4及EP300蛋白表达,分析EP300与SNHG4及SNHG4与GPX4表达的相关性。结果 SNHG4在乳腺癌组织中表达高于癌旁组织(P＜0.01),且在侵袭转移能力强的Basal-Like型及ER(-)乳腺癌中高表达(P＜0.01),SNHG4高表达与乳腺癌患者的总生存期(OS)及无病生存期(DFS)短相关(P＜0.01)。敲降SNHG4导致细胞活力降低(P＜0.01),且该作用可被铁死亡抑制剂逆转。机制方面,SNHG4通过上调GPX4表达抑制铁死亡,SNHG4上游可受到组蛋白乙酰基转移酶EP300的正向调控,EP300与SNHG4的表达正相关(P＜0.01)。结论 SNHG4在乳腺癌中高表达且可通过EP300-SNHG4-GPX4轴抑制乳腺癌细胞铁死亡。

关键词: 乳腺癌, 铁死亡, 谷胱甘肽过氧化物酶-4, lncRNA SNHG4, EP300

Abstract: Objective This study aimed to investigate the expression of lncRNA SNHG4 in breast cancer and the mechanism of regulating ferroptosis in breast cancer cells. Methods The tumor tissues of 100 breast cancer patients who underwent surgery in our hospital from January 2017 to December 2018 and the adjacent tissues 3-5 cm away from the tumor edge were collected,and the expression of SNHG4 in breast cancer tissues and paired adjacent tissues was analyzed by RT-PCR.The MDA-MB-468 cell line of breast cancer with SNHG4 knockdown and Hs578T cell line of breast cancer with SNHG4 overexpression were constructed.The CCK-8 assay was used to measure the effect of SNHG4 on the proliferation of breast cancer cells.The changes of iron and ROS were detected by iron content assay kit and MDA assay kit.Western blot was used to detect the expression of GPX4 and EP300 proteins.The correlation between the expression of SNHG4 and EP300,and SNHG4 and GPX4 was analyzed. Results The expression of SNHG4 in breast cancer tissues was higher than that in adjacent tissues(P＜0.01),and it was highly expressed in Basal-Like type and ER(-)breast cancer with strong invasion and migration(P＜0.01).The high expression of SNHG4 was correlated with the short overall survival(OS)and disease-free survival(DFS)of breast cancer patients(P＜0.01).Knockdown of SNHG4 resulted in decreased cell viability(P＜0.01),and this effect could be reversed by inhibitor of ferroptosis.In terms of mechanism,SNHG4 inhibited ferroptosis by up-regulating the expression of GPX4.The upstream of SNHG4 could be positively regulated by histone acetyltransferase,EP300,and EP300 was positively correlated with the expression of SNHG4(P＜0.01). Conclusion SNHG4 is highly expressed in breast cancer and can inhibit ferroptosis of breast cancer cells through EP300-SNHG4-GPX4 axis.

Key words: Breast cancer, Ferroptosis, Glutathione peroxidase-4(GPX4), lncRNA SNHG4, EP300

中图分类号:

R737.9

隋世尧, 郑玮, 杨子涵, 庞达. lncRNA SNHG4通过EP300-SNHG4-GPX4轴抑制乳腺癌细胞铁死亡[J]. 实用肿瘤学杂志, 2023, 37(3): 215-223.

SUI Shiyao, ZHENG Wei, YANG Zihan, PANG Da. LncRNA SNHG4 inhibits ferroptosis of breast cancer through EP300-SNHG4-GPX4 axis[J]. Journal of Practical Oncology, 2023, 37(3): 215-223.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.03.004

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I3/215

参考文献

1 Sung H,Ferlay J,Siegel RL,Laversanne M,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Ozkan E,Bakar-Ates Ferroptosis:A trusted ally in combating drug resistance in cancer[J].Curr Med Chem,2022,29:41-55.
3 Zhang X,Sui S,Wang L,et al.Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of Cisplatin[J].J Cell Physiol,2020,235:3425-3437.
4 SUI S,ZHANG J,XU S,et al.Ferritinophagy is required for the induction of ferroptosis by the Bromodomain protein BRD4 Inhibitor(+)-JQ1 in cancer cells[J].Cell Death Dis,2019,10:331-348.
5 XU R,FENG F,YU X,et al.LncRNA SNHG4 promotes tumour growth by sponging miR-224-3p and predicts poor survival and recurrence in human osteosarcoma[J].Cell Prolif,2018,51:e12515.
6 LI H,HONG J,Wijayakulathilaka W.Long non-coding RNA SNHG4 promotes cervical cancer progression through regulating c-Met via targeting miR-148a-3p[J].Cell Cycle,2019,18:3313-3324.
7 WANG ZY,DUAN Y,WANG P.SP1-mediated upregulation of lncRNA SNHG4 functions as a CeRNA for miR-377 to facilitate prostate cancer progression through regulation of ZIC5[J].J Cell Physiol,2020,235:3916-3927.
8 WU K,FAN D,ZHAO H,et al:Dynamics of Histone Acetylation during human early Embryogenesis[J].Cell Discov,2023,9:29.
9 BenAyed-Guerfali D,Kifagi C,BenKridis-Rejeb W,et al.The identification by exome sequencing of candidate genes in BRCA-Negative Tunisian patients at a high risk of hereditary breast/ovarian cancer[J].Genes(Basel),2022,13.
10 LI CH,FANG CY,CHAN MH,et al.The activation of EP300 by F11R leads to EMT and acts as a prognostic factor in triple-negative breast cancers[J].J Pathol Clin Res,2023,9(3):165-181.
11 LV L,HUANG B,YI L,et al.Long non-coding RNA SNHG4 enhances RNF14 mRNA stability to promote the progression of colorectal cancer by recruiting TAF15 protein[J].Apoptosis,2022,28(3-4):414-431.
12 LIU J,ZHAO S,YANG C,et al:Establishment and validation of a multigene model to predict the risk of relapse in Hormone receptor-positive early-stage Chinese breast cancer patients[J].Chin Med J(Engl),2022,136(2):184-193.
13 LI K,XU K,HE Y,et al.Oxygen Self-Generating nanoreactor mediated ferroptosis activation and immunotherapy in triple-negative breast cancer[J].ACS Nano,2023,17(5):4667-4687.
14 QI W,LI Z,XIA L,et al.LncRNA GABPB1-AS1 and GABPB1 regulate oxidative stress during erastin-induced ferroptosis in HepG2 hepatocellular carcinoma cells[J].Sci Rep,2019,9:16185.
15 ZHAO J,YANG S,LV C,et al.Cancer associated fibroblasts suppressed ferroptosis in glioblastoma via upregulating lncRNA DLEU1[J].Am J Physiol Cell Physiol,2023,324(5):C1039-C1052.
16 GAI C,LIU C,WU X,et al.MT1DP loaded by folate-modified liposomes sensitizes erastin-induced ferroptosis via regulating miR-365a-3p/NRF2 axis in non-small cell lung cancer cells[J].Cell Death Dis,2020,11(9):751-762.
17 MAO C,WANG X,LIU Y,et al:A G3BP1-interacting lncRNA promotes ferroptosis and apoptosis in cancer via nuclear sequestration of p53[J].Cancer Res,2018,78:3484-3496.
18 YU H,HAN Z,XU Z,et al.RNA sequencing uncovers the key long non-coding RNAs and potential molecular mechanism contributing to XAV939-mediated inhibition of non-small cell lung cancer[J].Oncol Lett,2019,17:4994-5004.

[1]	马艳玲, 钱立庭, 魏东华, 尹惠萍, 张娟, 张小鹏. 2014—2017年安徽省合肥市城市乳腺癌高危人群筛查率及其影响因素分析[J]. 实用肿瘤学杂志, 2023, 37(3): 200-206.
[2]	张庆怀, 韩阿蒙, 杨森, 李秀梅, 赵健鑫, 张彦秋. 乳腺癌患者保乳术后五种放疗技术的疗效比较研究[J]. 实用肿瘤学杂志, 2023, 37(3): 224-229.
[3]	杨帅, 王新恒, 吴佳乐, 付子彤, 魏博, 杨灵冰, 许守平. 单细胞测序技术在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 287-292.
[4]	张馨, 吴羡美, 李虹, 刘晓舟, 孔德文, 陈琢. 1990—2019年中国女性人群归因于代谢危险因素的乳腺癌疾病负担[J]. 实用肿瘤学杂志, 2023, 37(2): 107-111.
[5]	刘欣欣, 马西元, 缪美琪, 王语晴, 陈晶. IL-6及其受体在乳腺癌治疗中的作用研究进展[J]. 实用肿瘤学杂志, 2023, 37(2): 149-154.
[6]	冯诚天, 黄芙蓉, 姜永冬. 脂质代谢与乳腺癌曲妥珠单抗耐药性机制的相关性研究[J]. 实用肿瘤学杂志, 2023, 37(2): 155-159.
[7]	文世超, 王静萱. 铜依赖性细胞死亡及铜在乳腺癌治疗中的研究现状[J]. 实用肿瘤学杂志, 2023, 37(2): 185-189.
[8]	余银平, 蔺嘉楠, 王立中, 蒋威华. 癌源性外泌体对乳腺癌MCF-7细胞生物学行为的影响[J]. 实用肿瘤学杂志, 2023, 37(1): 26-31.
[9]	朱兴, 张冰, 赵静, 纪洪. 铁死亡在泌尿系统肿瘤中的作用及其机制研究进展[J]. 实用肿瘤学杂志, 2023, 37(1): 73-78.
[10]	教冲, 史雨鑫, 徐浩译, 马斌林, 董朝. 二甲双胍对不同亚型乳腺癌伴2型糖尿病患者预后影响的研究[J]. 实用肿瘤学杂志, 2022, 36(6): 531-537.
[11]	吴蕊玥, 朱凯丽, 杨景茹, 令晓玲. HER2低表达乳腺癌的临床研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 570-575.
[12]	王钦, 刘军杰, 陆秀鑫, 吴雅菲, 张文皓. 基于铁死亡的纳米联合疗法在恶性肿瘤治疗中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 429-434.
[13]	王星涵, 吕雅蕾. 曲妥珠单抗耐药机制及HER2阳性乳腺癌耐药后的治疗策略[J]. 实用肿瘤学杂志, 2022, 36(5): 445-451.
[14]	康子曼, 杨聃琳, 孙建男. 乳腺MRI图像纹理分析在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 472-476.
[15]	李智慧, 李志高. 恩美曲妥珠单抗T-DM1在HER2阳性乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 477-482.

lncRNA SNHG4通过EP300-SNHG4-GPX4轴抑制乳腺癌细胞铁死亡

LncRNA SNHG4 inhibits ferroptosis of breast cancer through EP300-SNHG4-GPX4 axis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价